Analyst reads last rites after heart failure scuttles Bristol hep C study
A safety crisis has forced Bristol-Myers Squibb ($BMY) to slam the brakes on a mid-stage study of a hepatitis C drug, threatening the future of a program that was at the heart of a recent $2.5 billion buyout. And as investigators scrambled to see if ...
Bristol-Myers suspends hepatitis C treatment study
Bristol-Myers Halts Hepatitis C Trial as Pipeline Stumbles
Bristol-Myers Halts Hepatitis C Study on Safety Issue